WGS Stock Forecast & Price Target

GeneDx Holdings is a company that is focused on genomics and is pioneering exome and genome sequencing for rare and ultra-rare genetic disorders. The company believes that these tests will become the standard for diagnosing genetic disease, ultimately transforming healthcare from reactive to proactive. The recent policy update from Carelon, which acknowledges WGS (whole exome and genome sequencing) as a first-line diagnostic tool, is a potential structural ASP de-risking event that could drive ~$100 in incremental ASP by H2 2027. While the lowered FY26 guidance was a tough update, their acquisition of Fabric Genomics should help expand their reach globally and provide another source of revenue. Despite the headwinds, the company remains positive, with expectations to return to positive adjusted net income in Q3'26 and end the year positively.

GeneDx Holdings is positioned to transform healthcare and advance precision medicine with its focus on genomics and pediatric rare disease diagnostics, however, their recent revenue results and guidance have underperformed expectations, potentially due to headwinds from mix and softness in their non-core business. With risks including potential apprehension from geneticists, uncertainty in the rare disease market, and dependence on payor coverage decisions, it may take several years for GeneDx to see the full potential of their recent GUARDIAN study results and enter the newborn screening market, potentially impacting their financials in the short-term.